...Therapeutics Inc. have platforms for discovering small molecules that bind target RNA molecules. Another company, Twentyeight-Seven Therapeutics...

...lot faster, and we may be out raising money in next three years.” COMPANY PROFILE Twentyeight-Seven Therapeutics...
...Arrakis Therapeutics Inc., Waltham, Mass. Expansion Therapeutics Inc., San Diego, Calif. Ribometrix Inc., Durham, N.C. Twentyeight-Seven Therapeutics...
...myelocytomatosis viral oncogene homolog SNRP200 - Small nuclear ribonucleoprotein U5 subunit 200 Karen Tkach Tuzman, Associate Editor Twentyeight-Seven Therapeutics Lin-28...

...existing shareholder Samsara BioCapital. Sofinnova Partners, OUP top off 28-7’s A round Non-coding RNA company Twentyeight-Seven Therapeutics...

...is also the CEO of Syndax Pharmaceuticals Inc. (NASDAQ:SNDX). Twentyeight-Seven Therapeutics Inc., Cambridge, Mass. Elizabeth S. Eaton non-coding RNA Twentyeight-Seven Therapeutics...

...joined Twentyeight-Seven's board. Morrison is also the CEO of Syndax Pharmaceuticals Inc. (NASDAQ:SNDX). Elizabeth S. Eaton non-coding RNA Twentyeight-Seven Therapeutics...